COMPASS Pathways plc
NASDAQCOMPASS Pathways reported Q1 earnings on May 13 that beat estimates and flagged an accelerated FDA review timeline, delivering a jolt to a stock that had already climbed 69% over the prior month — and leaving a still-elevated short base scrambling to adjust. The earnings beat was clear. COMPASS posted Q1 EPS of -$0.30 against a -$0.34 consensus estimate, and shares surged on the…
CMPS short interest surges 26.7% in one week to 11.04M shares, driven by biotech volatility ahead of May 7 earnings.
Snapshot as of 22 Jun 2026
COMPASS Pathways reported Q1 earnings on May 13 that beat estimates and flagged an accelerated FDA review timeline, delivering a jolt to a stock that had already climbed 69% over the prior month — and leaving a…
COMPASS Pathways reports Q1 2026 results on May 7 after a month that has completely re-priced the stock — and the short-side has scrambled to keep up. Options positioning has actually turned more bullish into the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CMPS — free to start on ORTEX.
Sign up for free →Open CMPS on ORTEX